Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection.
COVID-19
Inflammasome
Innate immune response
NLRP3
SARS-CoV2
Vaccine.
Journal
Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
21
05
2021
accepted:
15
02
2022
revised:
12
02
2022
pubmed:
12
8
2022
medline:
28
9
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
The novel coronavirus SARS-CoV-2, responsible for the COVID-19 outbreak, has become a pandemic threatening millions of lives worldwide. Recently, several vaccine candidates and drugs have shown promising effects in preventing or treating COVID-19, but due to the development of mutant strains through rapid viral evolution, urgent investigations are warranted in order to develop preventive measures and further improve current vaccine candidates. Positive-sense-single-stranded RNA viruses comprise many (re)emerging human pathogens that pose a public health problem. Our innate immune system and, in particular, the interferon response form an important first line of defense against these viruses. Flexibility in the genome aids the virus to develop multiple strategies to evade the innate immune response and efficiently promotes their replication and infective capacity. This review will focus on the innate immune response to SARS-CoV-2 infection and the virus' evasion of the innate immune system by escaping recognition or inhibiting the production of an antiviral state. Since interferons have been implicated in inflammatory diseases and immunopathology along with their protective role in infection, antagonizing the immune response may have an ambiguous effect on the clinical outcome of the viral disease. This pathology is characterized by intense, rapid stimulation of the innate immune response that triggers activation of the Nod-like receptor family, pyrin-domain-containing 3 (NLRP3) inflammasome pathway, and release of its products including the pro-inflammatory cytokines IL-6, IL-18, and IL-1β. This predictive view may aid in designing an immune intervention or preventive vaccine for COVID-19 in the near future.
Identifiants
pubmed: 35953688
doi: 10.1007/s10753-022-01651-y
pii: 10.1007/s10753-022-01651-y
pmc: PMC9371632
doi:
Substances chimiques
Antiviral Agents
0
COVID-19 Vaccines
0
Inflammasomes
0
Interleukin-18
0
Interleukin-6
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Pyrin
0
Interferons
9008-11-1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1849-1863Subventions
Organisme : University Grants Commission
ID : F.4-2/2006 (BSR)/BL/18-19/0117
Organisme : Japan Society for the Promotion of Science
ID : JSPS/OF322
Organisme : Japan Society for the Promotion of Science
ID : ID No. P19108
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Huang, C., et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395: 497–506.
Nagaraja, S., et al. 2022. Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats. Journal of Leukocyte Biology 111: 497–508.
pubmed: 34057760
doi: 10.1002/JLB.4COVHR0221-093RR
Chen, N., et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395: 507–513.
pubmed: 32007143
pmcid: 7135076
doi: 10.1016/S0140-6736(20)30211-7
Wu, A., et al. 2020. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe 27: 325–328.
doi: 10.1016/j.chom.2020.02.001
Lu, R., et al. 2020. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395: 565–574.
pubmed: 32007145
pmcid: 7159086
doi: 10.1016/S0140-6736(20)30251-8
Hoffmann, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 18: 271–280.
doi: 10.1016/j.cell.2020.02.052
Xu, X.W., et al. 2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. The BMJ 368: m606.
Medzhitov, et al. 2001. Toll-like receptors and innate immunity. Nature Reviews Immunology 1: 135–145.
pubmed: 11905821
doi: 10.1038/35100529
Bauernfeind, et al. 2011. Inflammasomes: Current understanding and open questions. Cellular and Molecular Life Sciences 68: 765–783.
pubmed: 21072676
doi: 10.1007/s00018-010-0567-4
Prompetchara, et al. 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific Journal of Allergy and Immunology 38: 1–9.
pubmed: 32105090
Lim, et al. 2016. Human coronaviruses: a review of virus-host interactions. Diseases 4.
Chen, I.Y., et al. 2019. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Frontiers in Microbiology 10: 50.
pubmed: 30761102
pmcid: 6361828
doi: 10.3389/fmicb.2019.00050
Chen, N., et al. 2017. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69: 297–304.
pubmed: 28374903
pmcid: 7165898
doi: 10.1002/iub.1625
Ashraf, U.M., et al. 2021. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiological Genomics 53: 51–60.
pubmed: 33275540
doi: 10.1152/physiolgenomics.00087.2020
De Marcken, M., et al. 2019. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Science Signaling 12: eaaw1347.
Olejnik, J., et al. 2018. Toll-like receptor 4 in acute viral infection: too much of a good thing. PLoS Pathog 14: e1007390.
Zhu, J., et al. 2020. Infectious bronchitis virus inhibits activation of the TLR7 pathway, but not the TLR3 pathway. Archives of Virology 165: 2037–2043.
pubmed: 32524263
pmcid: 7286419
doi: 10.1007/s00705-020-04690-8
Kawasaki, T., and T. Kawai. 2014. Toll-like Kawai receptor signaling pathways. Front Immunol 5:461 Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, Diamond MS, Gale M Jr, 2006 Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. Journal of Virology 80: 9424–9434.
Zhou, H., et al. 2013. IRAK-M mediates Toll-like receptor/IL-1R-induced NFkappaB activation and cytokine production. EMBO Journal 32: 583–596.
pubmed: 23376919
pmcid: 3579143
doi: 10.1038/emboj.2013.2
Loo, Y.-M., and M. Gale. 2011. Immune signaling by RIG-I-like receptors. Immunity 34: 680–692.
pubmed: 21616437
pmcid: 3177755
doi: 10.1016/j.immuni.2011.05.003
Seth, R.B., et al. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell 122: 669–682.
pubmed: 16125763
doi: 10.1016/j.cell.2005.08.012
Li, H., Y. Wang, M. Ji, F. Pei, Q. Zhao, Y. Zhou, Y. Hong, S. Han, J. Wang, Q. Wang, Q. Li, and Y. Wang. 2020. Transmission routes analysis of SARS-CoV-2: A systematic review and case report. Front Cell Dev Biol. 10 (8): 618.
doi: 10.3389/fcell.2020.00618
Morrison. J., and A. García-Sastre. 2014. STAT2 signaling and dengue virus infection. JAKSTAT 3: e27715.
Qin, S., et al. 2021. Analyzing master regulators and scRNA-seq of COVID-19 patients reveals an underlying anti-SARS-CoV-2 mechanism of ZNF proteins. Brief Bioinformation 27: bbab118.
Mu, J., et al. 2020. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov 6: 65.
pubmed: 32953130
pmcid: 7490572
doi: 10.1038/s41421-020-00208-3
Wani, S.A., et al. 2019. Contrasting gene expression profiles of monocytes and lymphocytes from peste-des-petits-ruminants virus infected goats. Frontiers in Immunology 10: 1463.
pubmed: 31333643
pmcid: 6624447
doi: 10.3389/fimmu.2019.01463
Mehta, P., et al. 2020. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033–1034.
pubmed: 32192578
pmcid: 7270045
doi: 10.1016/S0140-6736(20)30628-0
Zhang, C., et al. 2020. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. International Journal of Antimicrobial Agents 55: 105954.
Carvalho, T. 2021. The first 12 months of COVID-19: A timeline of immunological insights. Nature Reviews Immunology 21: 245–256.
pubmed: 33723416
pmcid: 7958099
doi: 10.1038/s41577-021-00522-1
Kanneganti, T.-D. 2010. Central roles of NLRs and inflammasomes in viral infection. Nature Reviews Immunology 10: 688–698.
pubmed: 20847744
pmcid: 3909537
doi: 10.1038/nri2851
Guo, H., et al. 2015. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nature Medicine 21: 677–687.
pubmed: 26121197
pmcid: 4519035
doi: 10.1038/nm.3893
Li, Q., and I.M. Verma. 2002. NF-kappaB regulation in the immune system. Nature Reviews Immunology 2: 725–734.
pubmed: 12360211
doi: 10.1038/nri910
Hayden, M.S., et al. 2006. NF-κB and the immune response. Oncogene 25: 6758–6780.
pubmed: 17072327
doi: 10.1038/sj.onc.1209943
De Diego, M.L., et al. 2014. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. Journal of Virology 88: 913.
doi: 10.1128/JVI.02576-13
Wang, X., et al. 2020. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion.” Cellular & molecular immunology 7: 1–3. https://doi.org/10.1038/s41423-020-0424-9 .
Wang, W., et al. 2007. Up-regulation of IL-6 and TNF-alpha induced by SARScoronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Research 128: 1–8.
pubmed: 17532082
pmcid: 7114322
doi: 10.1016/j.virusres.2007.02.007
Sun, B., et al. 2017. Dengue virus activates cGAS through the release of mitochondrial DNA. Science and Reports 7: 3594.
doi: 10.1038/s41598-017-03932-1
Uno, N., and T.M. Ross. 2018. Dengue virus and the host innate immune response. Emerg Microbes Infect 7: 167.
pubmed: 30301880
pmcid: 6177401
doi: 10.1038/s41426-018-0168-0
Lessler, J., et al. 2009. Incubation periods of acute respiratory viral infections: A systematic review. The Lancet Infectious Diseases 9: 291–300.
pubmed: 19393959
pmcid: 4327893
doi: 10.1016/S1473-3099(09)70069-6
Sa Ribero, M., et al. 2020. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathogens 16: e1008737.
Cameron, M.J., et al. 2012. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. PLoS One 7: e45842.
Minakshi, R., et al. 2009. The SARS coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor. PLoS One 4: e8342.
Blanco-Melo, D., et al. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181: 1036–1045.
pubmed: 32416070
pmcid: 7227586
doi: 10.1016/j.cell.2020.04.026
Hadjadj, J., et al. 2020. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369: 718–724.
pubmed: 32661059
pmcid: 7402632
doi: 10.1126/science.abc6027
Lowery, S.A. 2021. Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host & Microbe 29: 1052–1062.
doi: 10.1016/j.chom.2021.05.004
Randall, R.E., and S. Goodbourn. 2008. Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. Journal of General Virology 89: 1–47.
pubmed: 18089727
doi: 10.1099/vir.0.83391-0
Arunachalam, P.S., et al. 2020. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369: 1210–1220.
pubmed: 32788292
pmcid: 7665312
doi: 10.1126/science.abc6261
Israelow, B., et al. 2020. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. Journal of Experimental Medicine 217: e20201241.
Banerjee, A.K., et al. 2020. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183: 1325-1339.e21.
pubmed: 33080218
pmcid: 7543886
doi: 10.1016/j.cell.2020.10.004
Gordon, D.E., et al. 2020. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Preprint. bioRxiv 03.22.002386.
Xia, H. et al., 2020. Evasion of type I interferon by SARS-CoV-2. Cell Reports 33: 108234.
Lei, X., et al. 2020. Activation and evasion of type I interferon responses by SARS-CoV-2. Nature Communications 11: 3810.
pubmed: 32733001
pmcid: 7392898
doi: 10.1038/s41467-020-17665-9
Mulchandani, R., et al. 2021. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. European Journal of Clinical Investigation 51: e13429.
de la Rica, R., et al. 2020. COVID-19: in the eye of the cytokine storm. Front Immunology 11: 558898.
Xiong, J., et al. 2020. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. Journal of Affective Disorders 277: 55–64.
pubmed: 32799105
pmcid: 7413844
doi: 10.1016/j.jad.2020.08.001
Wu, N.C., et al. 2020. An alternative binding mode of IGHV3–53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Reports 33:108274.
Yang, Q., et al. 2020. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. Elife 9: e61552.
Karki, R., et al. 2021. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184: 149-168.e17.
pubmed: 33278357
doi: 10.1016/j.cell.2020.11.025
Chua, R.L., et al. 2020. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nature biotechnology 38: 970–979.
pubmed: 32591762
doi: 10.1038/s41587-020-0602-4
Liao, M., et al. 2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature medicine 26: 842–844.
pubmed: 32398875
doi: 10.1038/s41591-020-0901-9
Mathew, D., et al. 2020. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369: eabc8511.
Schulte-Schrepping, J., et al. 2020. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182: 1419–1440.
pubmed: 32810438
pmcid: 7405822
doi: 10.1016/j.cell.2020.08.001
Su, H., et al. 2020. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international 98: 219–227.
pubmed: 32327202
pmcid: 7194105
doi: 10.1016/j.kint.2020.04.003
Wilk, A.J., et al. 2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature medicine 26: 1070–1076.
pubmed: 32514174
pmcid: 7382903
doi: 10.1038/s41591-020-0944-y
Schultze, A., et al. 2020. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: An observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine 8: 1106–1120.
pubmed: 32979987
pmcid: 7515601
doi: 10.1016/S2213-2600(20)30415-X
Kuri-Cervantes, L., et al. 2020. Comprehensive mapping of immune perturbations associated with severe COVID-19. Science immunology 5: eabd7114.
Giamarellos-Bourboulis, E.J., et al. 2020. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell host & microbe 27: 992–1000.
doi: 10.1016/j.chom.2020.04.009
Swanson, K.V., et al. 2019. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nature Reviews Immunology 19: 477–489.
pubmed: 31036962
pmcid: 7807242
doi: 10.1038/s41577-019-0165-0
Ruland, J. 2014. Inflammasome: Putting the pieces together. Cell 156: 1127–1129.
pubmed: 24630715
doi: 10.1016/j.cell.2014.02.038
Patton, L.M., et al. 1995. Interleukin-1 beta-induced neutrophil recruitment and acute lung injury in hamsters. Inflammation 19: 23–29.
pubmed: 7705884
doi: 10.1007/BF01534377
Kolb, M., et al. 2001. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. The Journal of Clinical Investigation 107: 1529–1536.
pubmed: 11413160
pmcid: 200196
doi: 10.1172/JCI12568
Azkur, A.K., et al. 2020. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 75: 1564–1581.
pubmed: 32396996
doi: 10.1111/all.14364
Alosaimi, B., et al. 2020. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract. Cytokine 126: 154895.
Min, C.K., et al. 2016. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Science and Reports 6: 25359.
doi: 10.1038/srep25359
Meduri, G.U., et al. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062–1073.
Park, W.Y., et al. 2001. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 164: 1896–1903.
pubmed: 11734443
doi: 10.1164/ajrccm.164.10.2104013
Beigel, J.H., et al. 2005. Avian influenza A (H5N1) infection in humans. New England Journal of Medicine 353: 1374–1385.
pubmed: 16192482
doi: 10.1056/NEJMra052211
Tumpey, T.M., et al. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77–80.
pubmed: 16210530
doi: 10.1126/science.1119392
Kobasa, D., et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319–323.
pubmed: 17230189
doi: 10.1038/nature05495
Fu, B., et al. 2020. Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translational Medicine 18: 164.
pubmed: 32290839
pmcid: 7154566
doi: 10.1186/s12967-020-02339-3
Fung, S.Y., et al. 2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses. Emerg Microbes Infect 9: 558–570.
pubmed: 32172672
doi: 10.1080/22221751.2020.1736644
Channappanavar, R., et al. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host & Microbe 19: 181–193.
doi: 10.1016/j.chom.2016.01.007
Nieto-Torres, J.L., et al. 2014. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathogens 10: e1004077.
Fu, Y., et al. 2020. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools. Virol Sin. https://doi.org/10.1007/s12250-020-00207-4 .
doi: 10.1007/s12250-020-00207-4
pubmed: 33044659
pmcid: 8257821
Kuriakose, T., et al. 2016. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Science Immunology 1: aag2045.
Rebsamen, M., et al. 2009. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Reports 10: 916–922.
pubmed: 19590578
pmcid: 2726668
doi: 10.1038/embor.2009.109
Yabal, M., et al. 2014. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Reports 7: 1796–1808.
pubmed: 24882010
doi: 10.1016/j.celrep.2014.05.008
Allen, I.C., et al. 2009. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30: 556–565.
pubmed: 19362020
pmcid: 2803103
doi: 10.1016/j.immuni.2009.02.005
Hornung, V., et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology 9: 847–856.
pubmed: 18604214
pmcid: 2834784
doi: 10.1038/ni.1631
Mariathasan, S., et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228–232.
pubmed: 16407890
doi: 10.1038/nature04515
Petrilli, V., et al. 2007. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death and Differentiation 14: 1583–1589.
pubmed: 17599094
doi: 10.1038/sj.cdd.4402195
Nieto-Torres, J.L., et al. 2015. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 485: 330–339.
pubmed: 26331680
doi: 10.1016/j.virol.2015.08.010
Zhou, R., et al. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221–225.
pubmed: 21124315
doi: 10.1038/nature09663
Chen, C.C., et al. 2011. ORF8a of SARS-CoV forms an ion channel: Experiments and molecular dynamics simulations. Biochimica et Biophysica Acta 1808: 572–579.
pubmed: 20708597
doi: 10.1016/j.bbamem.2010.08.004
Castaño-Rodriguez, C., et al. 2018. Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. mBio 9: e02325–17.
Shi, C.S., et al. 2019. SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov 5: 101.
pubmed: 31231549
pmcid: 6549181
doi: 10.1038/s41420-019-0181-7
Astuti, I. 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes and Metabolic Syndrome 14: 407–412.
Zhao, C., and W. Zhao. 2020. NLRP3 inflammasome—a key player in antiviral responses. Frontiers in Immunology 11: 211.
pubmed: 32133002
pmcid: 7040071
doi: 10.3389/fimmu.2020.00211
de Castro-Jorge, L.A., et al. 2019. The NLRP3 inflammasome is involved with the pathogenesis of Mayaro virus. PLoS Pathogens 15: e1007934.
Bertocchi, I., et al. 2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: lessons for drug repurposing. British Journal of Pharmacology 177: 4921–4930. https://doi.org/10.1111/bph.15229 . Epub 2020 Aug 26. PMID: 32776354; PMCID: PMC7436458.
Yap, J.K., et al. 2020. Inflammasomes and pyroptosis as therapeutic targets for COVID-19. The Journal of Immunology 205: 307–312.
pubmed: 32493814
doi: 10.4049/jimmunol.2000513
van den Berg, D.F., et al. 2020. Severe COVID-19: NLRP3 inflammasome dysregulated. Frontiers in Immunology 11: 1580.
pubmed: 32670297
pmcid: 7332883
doi: 10.3389/fimmu.2020.01580
Rodrigues, T.S., et al. 2020. Inflammasome activation in COVID-19 patients. medRxiv.
Wozniak, A.L., et al. 2010. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathogens 6: e1001087.
Farag, N., et al., 2020. Viroporins and inflammasomes: a key to understand virus-induced inflammation. The International Journal of Biochemistry & Cell Biology 122: 105738.
Issa, E., et al. 2020. SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems 5: e00266–20.
De Diego, M.L., et al. 2014. Inhibition of NF-κBmediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. Journal of Virology 88: 913–924.
doi: 10.1128/JVI.02576-13
Ratajczak, M.Z., et al. 2020. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leukemia 34: 1726–1729.
pubmed: 32483300
pmcid: 7262681
doi: 10.1038/s41375-020-0887-9
Ribeiro, D.E., et al. 2020. Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Molecular Psychiatry 1–16.
Rodrigues, T.S., et al. 2021. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. Journal of Experimental Medicine 218: e20201707.
Bok, K., et al. 2021. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity.
McLellan, J.S., et al. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342: 592–598.
pubmed: 24179220
pmcid: 4461862
doi: 10.1126/science.1243283
Crank, M.C., et al. 2019. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365: 505–509.
pubmed: 31371616
doi: 10.1126/science.aav9033
Pallesen, J., et al. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences 114: E7348–E7357.
doi: 10.1073/pnas.1707304114
Marian, A.J. 2021. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovascular Pathology 50: 107278.